



Kubota Pharmaceutical Holdings Co., Ltd. to Present at Seminar for the Pacific Northwest Chapter of the Society for Information Display

Seattle (August 30, 2023) — Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) (“Kubota Pharma” or the “Company”) announced today that Dr. Ryo Kubota, Chairman, President, and CEO, will speak at a seminar on September 6, 2023 at 6:00 pm – 7:00 pm PDT for the Pacific Northwest Chapter of the Society for Information Display (SID). Please click [here](#) for more details on the seminar.

Dr. Kubota will give a presentation entitled “Diagnosis and Treatment of Disease: The Role for Retinal Imaging and AR.” Retinal imaging is a rapidly changing field that is becoming increasingly important for diagnosing a wide range of ophthalmic and neurological diseases. Recent developments have helped to reduce the size, weight, and cost of this technology, introducing the possibility that regular in-home monitoring may become a reality. New technology has also been applied toward the development of spectacle-based treatments for ophthalmic disease, including the use of augmented reality devices. An overview and the benefits and challenges associated with these technologies will be discussed.

The SID is a collective of leading scientists, engineers, corporate researchers, and business professionals from the display industry. Established in 1962, SID's mission is to advance display technology, a goal it continues to pursue today through the publication of the monthly Journal of SID, Information Display magazine, and the annual Digest of Technical Papers. These are presented at the yearly Display Week Symposium and Exhibition in spring. All these publications can be accessed online by members at no extra cost.

Dr. Kubota stated, “I am very honored to have the opportunity to speak at the SID for the first time. I look forward to discussing with top-class technicians, engineers, and researchers from around the world in this forum, and to furthering my research and product development in the future.”

About Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group’s pipeline includes a wearable device for myopia control using Kubota Glass technology and a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients. <https://www.kubotaholdings.co.jp/en/>

Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial

potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision,” the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Media and Investor Relations Contact:

Press and Media Inquiries

Phone: +81-3-6550-8928

Email: pr@kubotaholdings.co.jp

###